TWi Biotechnology begins Phase 2 trial for AC-203 in epidermolysis bullosa patients

TWi Biotechnology, a Taiwanese biopharmaceutical company, has initiated the enrollment of patients in a pivotal Phase 2 clinical trial evaluating its investigational drug, AC-203, for ... Read More